C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 860—Medical Device Classification ProceduresSubpart A—General

21 C.F.R. § 860.3 (2026)

Definitions

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1991–2024 20citing cases
At a glance

Courts have cited this section in 20 opinions since 1991, 1 of them in the last five years.

For the purposes of this part:

Class means one of the three categories of regulatory control for medical devices, defined as follows:

Class I means the class of devices that are subject only to the general controls authorized by or under sections 501 (adulteration), 502 (misbranding), 510 (registration), 516 (banned devices), 518 (notification and other remedies), 519 (records and reports), and 520 (general provisions) of the Federal Food, Drug, and Cosmetic Act. A device is in class I if:

(1) General controls are sufficient to provide reasonable assurance of the safety and effectiveness of the device, or

(2) There is insufficient information from which to determine that general controls are sufficient to provide reasonable assurance of the safety and effectiveness of the device or to establish special controls to provide such assurance, but the device is not life-supporting or life-sustaining, or for a use which is of substantial importance in preventing impairment of human health, and which does not present a potential unreasonable risk of illness or injury.

Class II means the class of devices that is or eventually will be subject to special controls. A device is in class II if general controls alone are insufficient to provide reasonable assurance of its safety and effectiveness and there is sufficient information to establish special controls, including the promulgation of performance standards, postmarket surveillance, patient registries, development and dissemination of guidelines (including guidelines for the submission of clinical data in premarket notification submissions in accordance with section 510(k) of the Federal Food, Drug, and Cosmetic Act), recommendations, and other appropriate actions as the Commissioner deems necessary to provide such assurance. For a device that is purported or represented to be for use in supporting or sustaining human life, the Commissioner shall examine and identify the special controls, if any, which are necessary to provide adequate assurance of safety and effectiveness, and describe how such controls provide such assurance.

Class III means the class of devices for which premarket approval is or will be required in accordance with section 515 of the Federal Food, Drug, and Cosmetic Act. A device is in class III if insufficient information exists to determine that general controls are sufficient to provide reasonable assurance of its safety and effectiveness, or that application of special controls described in the definition of “Class II” in this section in addition to general controls, would provide such assurance, and if, in addition, the device is life-supporting or life-sustaining, or for a use which is of substantial importance in preventing impairment of human health, or if the device presents a potential unreasonable risk of illness or injury.

Classification panel means one of the several advisory committees established by the Commissioner under section 513 of the Federal Food, Drug, and Cosmetic Act and part 14 of this chapter for the purpose of making recommendations to the Commissioner on the classification and reclassification of devices and for other purposes prescribed by the Federal Food, Drug, and Cosmetic Act or by the Commissioner.

Classification regulation means a section under parts 862 through 892 of this chapter that contains the identification (general description and intended use) and classification (class I, II or III) of a single device type or more than one related device type(s).

Commissioner means the Commissioner of Food and Drugs, Food and Drug Administration, United States Department of Health and Human Services, or the Commissioner's designee.

De Novo request means any submission under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act for a medical device, requesting classification into class I or class II, including all information submitted with or incorporated by reference therein.

FDA means the Food and Drug Administration.

General controls mean the controls authorized by or under sections 501 (adulteration), 502 (misbranding), 510 (registration, listing, and premarket notification), 516 (banned devices), 518 (notification and other remedies), 519 (records, reports, and unique device identification), and 520 (general provisions) of the Federal Food, Drug, and Cosmetic Act.

Generic type of device means a grouping of devices that do not differ significantly in purpose, design, materials, energy source, function, or any other feature related to safety and effectiveness, and for which similar regulatory controls are sufficient to provide reasonable assurance of safety and effectiveness.

Implant means a device that is placed into a surgically or naturally formed cavity of the human body. A device is regarded as an implant for the purpose of this part only if it is intended to remain implanted continuously for a period of 30 days or more, unless the Commissioner determines otherwise to protect human health.

Life-supporting or life-sustaining device means a device that is essential to, or that yields information that is essential to, the restoration or continuation of a bodily function important to the continuation of human life.

Petition means a submission seeking reclassification of a device in accordance with § 860.123.

Special controls mean the controls necessary to provide reasonable assurance of safety and effectiveness for a generic type of device that is class II. Special controls include performance standards, performance testing, postmarket surveillance, patient registries, development and dissemination of guidelines (including guidelines for the submission of clinical data in premarket notification submissions in accordance with section 510(k) of the Federal Food, Drug, and Cosmetic Act), recommendations, and other appropriate actions, as the Commissioner deems necessary to provide such assurance.

[86 FR 54846, Oct. 5, 2021]
The 20 cases that cite 21 C.F.R. § 860.3 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENJessen v. Mentor Corp., 158 Cal. App. 4th 1480 (Ct. App. 2008).
cites § 860.3 2×cited by 57 cases
Where it cites § 860.3
“§ 360c(a)(1)(A); 21 C.F.R. § 860.3 (c)(1)); an example of a Class II device, which involves a higher degree of risk, is an oxygen mask.”
2
GREENCharlotte Kennedy v. Collagen Corp., 67 F.3d 1453 (9th Cir. 1995).
cites § 860.3 3×cited by 50 cases
Where it cites § 860.3
“§ 360e(a)(l)(A); 21 C.F.R. § 860.3 (c)(1). Class II devices include items such as tampons and oxygen masks.”
The case’s holding
State common law claims of general applicability are not preempted by the Medical Device Amendments because they do not constitute specific requirements applicable to a particular device.
Later courts cite it for
“pre-market approval is supposed to benefit consumers, not create a rose garden, free from liability, for manufacturers.” · 2 citing courts
3
GREENRosci v. AcroMed, Inc., 669 A.2d 959 (Pa. Super. Ct. 1995).
cites § 860.3 3×cited by 26 cases
Where it cites § 860.3
“§ 360c(a)(l)(A); 21 C.F.R. § 860.3 (c)(1). Class II devices include items such as tampons and oxygen masks.”
The case’s holding
The learned intermediary doctrine does not bar claims for breach of express warranty, and federal medical device regulations do not preempt express warranty claims.
Later courts cite it for
“the intended 'user' in a case involving a prescription drug or device is, of course, the prescribing physician.” · 2 citing courts
4
GREENArmstrong v. Optical Radiation Corp., 50 Cal. App. 4th 580 (Ct. App. 1996).
cites § 860.3 3×cited by 25 cases
Where it cites § 860.3
“§ 360c(a)(l)(B); 21 C.F.R. § 860.3 (c)(2) (1996).) Finally, a device falls into class III (e.”
The case’s holding
State law requirements for negligence and strict liability are based on general principles of state tort law rather than rules specifically developed for medical devices.
Later courts cite it for
“based on general principles of state tort law which were not specifically developed with respect to medical devices” · 1 citing court
5
GREENSowell v. Bausch & Lomb, Inc., 230 A.D.2d 77 (N.Y. App. Div. 1st Dep't 1997).
cites § 860.3 3×cited by 20 cases
Where it cites § 860.3
“Class I medical devices are those which pose little or no threat to public health and are subject only to "general controls” related to their manufacture (21 USC § 360c [a] [1] [A]; 21 CFR 860.3 [c] [1]). They include devices such as tongue depressors.”
Later courts cite it for
“while a pma review is considerably more rigorous and detailed than the pre-market notification process at issue in med-tronic, it is, in fact, no more 'specific' a requirement.” · 3 citing courts
6
GREENBurgstahler v. AcroMed Corp., 670 A.2d 658 (Pa. Super. Ct. 1995).
cites § 860.3 4×cited by 9 cases
Where it cites § 860.3
“§ 360c(a)(1)(A); 21 C.F.R. § 860.3 (c)(1). Class II devices include items such as tampons and oxygen masks.”
7
GREENBioderm Skin Care, LLC v. Veasna \sandee\" Sok", 426 S.W.3d 753 (Tex. 2014).
cites § 860.3 1×cited by 47 cases
Where it cites § 860.3
“See 21 C.F.R. § 860.3 (c) (providing Class II devices are subject to special controls).”
The case’s holding
A claim constitutes a health care liability claim if expert testimony is required to prove or refute whether the treatment departed from accepted standards of care.
Later courts cite it for
“no one element, occurring independent of the other two, will recast a claim into a health care liability claim.” · 2 citing courts
8
GREENKanter v. Warner-Lambert Co., 99 Cal. App. 4th 780 (Ct. App. 2002).
cites § 860.3 1×cited by 36 cases
The case’s holding
A state law claim is preempted if it effectively requires a manufacturer to include additional or different information on a federally approved label.
Later courts cite it for
“when a state law claim . . . would effectively require a manufacturer to include additional or different information on a federally approved label, it is preempted” · 5 citing courts
9
GREENKandis L. Papike v. Tambrands Inc., 107 F.3d 737 (9th Cir. 1997).
cites § 860.3 1×cited by 97 cases
Where it cites § 860.3
“1996); 21 C.F.R. § 860.3 (c)(2) (1996). The FDA has promulgated regulations concerning tampon labeling “[t]o protect the public and to minimize the serious adverse effects of TSS.”
The case’s holding
Federal preemption applies to state failure-to-warn claims when the FDA establishes specific labeling requirements for a particular device.
Later courts cite it for
“to rule otherwise would allow the anomalous circumstance that a consumer is entitled to expect a product to perform more safely than its government-mandated warnings indicate.” · 3 citing courts
10
GREENOliver v. Johnson & Johnson, Inc., 863 F. Supp. 251 (W.D. Pa. 1994).
cites § 860.3 3×cited by 7 cases
Where it cites § 860.3
“” 21 C.F.R. § 860.3 (e)(2). Finally, class III devices are subject to the most extensive controls because they present a potential unreasonable risk of illness or injury.”
11
GREENWilliam E. Chambers v. Osteonics Corp., 109 F.3d 1243 (7th Cir. 1997).
cites § 860.3 1×cited by 32 cases
Where it cites § 860.3
“§ 860c(a)(l)(C) and 21 C.F.R. § 860.3 (c)(3). The IDE process allows a manufacturer with an experimental device to obtain FDA approval for the device with a less rigorous review process than usual.”
Later courts cite it for
“pursuant to this authority, congress may preempt state law.” · 2 citing courts
12
GREENEthicon, Inc. v. Food & Drug Admin., 762 F. Supp. 382 (D.D.C. 1991).
cites § 860.3 1×cited by 10 cases
Where it cites § 860.3
“21 C.F.R. § 860.3 (i). The Contact Lens case is not applicable here because, simply put, it concerned a different device.”
Later courts cite it for
“congress gave fda sweeping discretion in determining the classification of devices and therefore in judging the safety and effectiveness of medical devices.” · 2 citing courts
13
GREENParenteau v. Johnson & Johnson Orthopedics, Inc., 856 F. Supp. 61 (D.N.H. 1994).
cites § 860.3 1×cited by 9 cases
Where it cites § 860.3
“§ 360c(a)(l)(A)-(B); 21 C.F.R. § 860.3 (c)(1)-(2). Class II devices may also “be subject to recommendations, guidelines, post-marketing surveillance, the development of patient registries, and even the promulgation of specific performance standards, should the FDA deem them a…”
14
GREENIvy Sports Med., LLC v. Sebelius, 938 F. Supp. 2d 47 (D.D.C. 2013).
cites § 860.3 1×cited by 4 cases
Where it cites § 860.3
“See 21 C.F.R. § 860.3 (i). A device is categorized as postamendment if it was first proposed for use on or after May 28, 1976.”
15
cites § 860.3 2×cited by 11 cases
Where it cites § 860.3
“§ 360c(a)(l)(A); 21 C.F.R. § 860.3 (c)(1). Medical devices which involve some risk of injury are classified as Class II devices and are subject to “special controls,” including performance standards, use guidelines, and post-market surveillance programs.”
16
GREENPolymer Tech. Corp. v. Mimran, 975 F.2d 58 (2d Cir. 1992).
cites § 860.3 1×cited by 30 cases
Where it cites § 860.3
“” 21 C.F.R. § 860.3 (c)(3) (1991). Premarket approval is also required for the labelling on the solutions.”
Later courts cite it for
“as a general rule, trademark law does not reach the sale of genuine goods bearing a true mark even though the sale is not authorized by the mark owner.” · 3 citing courts
17
GREENJames v. Diva Int'l, Inc., 803 F. Supp. 2d 945 (S.D. Ind. 2011).
cites § 860.3 1×cited by 3 cases
Where it cites § 860.3
“The controls exercised over Class II devices are insufficient to determine safety or effectiveness of Class III devices; accordingly, Class III devices must be generally approved prior to being marketed through a premarket authorization procedure.”
18
GREENDow v. Baxter Healthcare Corp., 899 F. Supp. 822 (D. Mass. 1995).
cites § 860.3 3×cited by 1 case
Where it cites § 860.3
“§ 360k; 21 C.F.R. § 860.3 (c)(1) — (2). The FDA has classified the foley catheter, at issue here, as a Class II medical device.”
19
GREENMarino v. Gunnar Optiks LLC, 2024 IL App (1st) 231826, 262 N.E.3d 675.
cites § 860.3 1×cited by 1 case
Where it cites § 860.3
“21 C.F.R. § 860.3 (2021). Thus, as the circuit court observed, Class I medical devices include a broad range of commonly used products such as adhesive bandages ( 21 C.”
Later courts cite it for
“presently awaiting or receiving care and treatment from a medical professional.” · 1 citing court
20
GREENJessen v. Mentor Corp., 158 Cal. App. 4th 1480 (Ct. App. 2008).
cites § 860.3 2×cited by 1 case
Where it cites § 860.3
“§ 360c(a)(l)(A); 21 C.F.R. § 860.3 (c)(1) (2007)); an example of a class U device, which involves a higher degree of risk, is an oxygen mask.”
The case’s holding
State common law claims challenging the safety or labeling of a PMA-approved class III medical device are preempted by the Medical Device Amendments unless they rest on violation of FDA requirements.
Later courts cite it for
“the burden shifts to the plaintiff to show there is one or more triable issues of material fact regarding the defense after the defendant meets the burden of establishing all the elements of the affirmative defense” · 5 citing courts

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199120072024

One bar per year. Tallest: 4 cases in 1995. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Cal. Ct. App.49th Cir.3D.D.C.2Pa. Super. Ct.22d Cir.17th Cir.1Ill. App. Ct.1S.D. Ind.1

The 8 courts with the most citing cases, of 13 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com